The oncologists market size has grown steadily in recent years. It will grow from $20.21 billion in 2025 to $21.09 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to rising incidence of cancer globally, growing demand for specialized oncology care, expansion of hospital and clinic networks, advancements in diagnostic imaging technologies, increasing awareness of early cancer detection.
The oncologists market size is expected to see steady growth in the next few years. It will grow to $25.07 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to growth in personalized and targeted cancer therapies, adoption of digital oncology management solutions, technological innovations in immunotherapy and targeted therapy, expansion of oncology centers in emerging markets, increasing use of genomics and molecular diagnostics for treatment planning. Major trends in the forecast period include rising adoption of digital oncology platforms for patient management, increasing integration of ai and machine learning in cancer diagnosis, growing implementation of precision medicine and genomic profiling for personalized cancer therapy, rising automation in chemotherapy preparation and drug delivery, increasing iot-enabled monitoring of oncology equipment and patient data.
The increasing prevalence of cancer is expected to drive the growth of the oncologists market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body. Cancer prevalence refers to the number of new cancer cases occurring within a specific population over a defined period. Oncologists are medical professionals who specialize in the diagnosis and treatment of cancer, playing a key role in patient evaluation, disease diagnosis, and the selection of appropriate treatment options. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that approximately 18.1 million cancer survivors were living in the United States. This number is expected to increase to 22.5 million by 2032. Additionally, by 2040, annual new cancer cases are projected to reach 29.9 million, while cancer-related deaths are estimated to rise to 15.3 million. As a result, the rising prevalence of cancer is contributing to the expansion of the oncologists market.
Leading organizations in the oncologists market are concentrating on the establishment of AI-powered precision oncology centers to advance personalized cancer care, enhance diagnostic accuracy, and refine treatment strategies based on individual patient data and tumor-specific characteristics. AI-precision oncology centers are specialized healthcare facilities that apply artificial intelligence and machine learning technologies to deliver highly tailored cancer treatment. For instance, in January 2024, Apollo Cancer Centre, an India-based hospital, launched a new AI-enabled oncology center. This facility supports oncologists, patients, and caregivers in achieving optimal outcomes within a defined timeframe by harnessing the capabilities of AI technology. The proof-of-concept utilizes AI-driven tools to deliver precise diagnoses and real-time insights into patient conditions, enabling timely interventions and improved cancer management. Additionally, the center conducts comprehensive cancer risk assessments to identify patients who may benefit from targeted therapies or immunotherapy as part of personalized treatment plans.
In July 2024, Mumbai Oncocare (MOC) Cancer Care & Research Centre, an India-based hospital and physician clinic network providing oncology services, merged with Hemato Oncology Clinic for an undisclosed amount. Through this merger, Mumbai Oncocare seeks to strengthen its service offerings by integrating Hemato Oncology’s expertise, which includes a team of approximately 40 medical oncologists and hematologists. Hemato Oncology Clinic is an India-based hospital known for delivering advanced oncology care.
Major companies operating in the oncologists market are Abramson Cancer Center, MD Anderson Cancer Center of the University of Texas, Lilavati Hospital & Research Centre, Mount Elizabeth Hospital, Mount Miriam Cancer Hospital, Charité - Universitätsmedizin Berlin, General Electric Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Takeda Pharmaceuticals USA Inc., Becton Dickinson and Company, Cook Medical LLC, Terumo Corporation, AngioDynamics Inc., Thermo Fisher Scientific Inc., Illumina Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Incyte Corporation, Seattle Genetics Inc.
North America was the largest region in the oncologists market in 2025. The regions covered in the oncologists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncologists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the oncologists market by increasing the cost of importing diagnostic equipment, imaging systems, and specialized cancer therapeutics, affecting hospitals, diagnostic laboratories, and specialty clinics primarily in north america, europe, and asia-pacific. While tariffs may raise operational expenses, they also incentivize local production, investment in domestic manufacturing of medical devices and therapies, and diversification of supply chains, which can enhance accessibility and reduce reliance on imports.
The oncologists market research report is one of a series of new reports that provides oncologists market statistics, including oncologists industry global market size, regional shares, competitors with a oncologists market share, detailed oncologists market segments, market trends and opportunities, and any further data you may need to thrive in the oncologists industry. This oncologists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncologists are healthcare professionals who specialize in the diagnosis and treatment of cancer. They assess patients, identify the presence and type of cancer, and recommend appropriate treatment options. Oncologists are involved in the overall treatment and care of individuals with cancer.
The primary areas of cancer diagnostics and treatment handled by oncologists include cancer diagnostics and cancer treatment. Cancer diagnostics involves testing procedures used to confirm the presence of cancer and determine the tumor type. These services address indications such as lung cancer, colorectal cancer, breast cancer, liver cancer, bladder cancer, head and neck cancer, and prostate cancer, with end users including hospitals, diagnostic laboratories, diagnostic imaging centers, specialty clinics, academic institutions, and others.
The oncologists market includes revenues earned by entities by providing diagnoses and treats cancer, radiation oncologists and surgical oncologists. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The oncologists market size is expected to see steady growth in the next few years. It will grow to $25.07 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to growth in personalized and targeted cancer therapies, adoption of digital oncology management solutions, technological innovations in immunotherapy and targeted therapy, expansion of oncology centers in emerging markets, increasing use of genomics and molecular diagnostics for treatment planning. Major trends in the forecast period include rising adoption of digital oncology platforms for patient management, increasing integration of ai and machine learning in cancer diagnosis, growing implementation of precision medicine and genomic profiling for personalized cancer therapy, rising automation in chemotherapy preparation and drug delivery, increasing iot-enabled monitoring of oncology equipment and patient data.
The increasing prevalence of cancer is expected to drive the growth of the oncologists market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body. Cancer prevalence refers to the number of new cancer cases occurring within a specific population over a defined period. Oncologists are medical professionals who specialize in the diagnosis and treatment of cancer, playing a key role in patient evaluation, disease diagnosis, and the selection of appropriate treatment options. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that approximately 18.1 million cancer survivors were living in the United States. This number is expected to increase to 22.5 million by 2032. Additionally, by 2040, annual new cancer cases are projected to reach 29.9 million, while cancer-related deaths are estimated to rise to 15.3 million. As a result, the rising prevalence of cancer is contributing to the expansion of the oncologists market.
Leading organizations in the oncologists market are concentrating on the establishment of AI-powered precision oncology centers to advance personalized cancer care, enhance diagnostic accuracy, and refine treatment strategies based on individual patient data and tumor-specific characteristics. AI-precision oncology centers are specialized healthcare facilities that apply artificial intelligence and machine learning technologies to deliver highly tailored cancer treatment. For instance, in January 2024, Apollo Cancer Centre, an India-based hospital, launched a new AI-enabled oncology center. This facility supports oncologists, patients, and caregivers in achieving optimal outcomes within a defined timeframe by harnessing the capabilities of AI technology. The proof-of-concept utilizes AI-driven tools to deliver precise diagnoses and real-time insights into patient conditions, enabling timely interventions and improved cancer management. Additionally, the center conducts comprehensive cancer risk assessments to identify patients who may benefit from targeted therapies or immunotherapy as part of personalized treatment plans.
In July 2024, Mumbai Oncocare (MOC) Cancer Care & Research Centre, an India-based hospital and physician clinic network providing oncology services, merged with Hemato Oncology Clinic for an undisclosed amount. Through this merger, Mumbai Oncocare seeks to strengthen its service offerings by integrating Hemato Oncology’s expertise, which includes a team of approximately 40 medical oncologists and hematologists. Hemato Oncology Clinic is an India-based hospital known for delivering advanced oncology care.
Major companies operating in the oncologists market are Abramson Cancer Center, MD Anderson Cancer Center of the University of Texas, Lilavati Hospital & Research Centre, Mount Elizabeth Hospital, Mount Miriam Cancer Hospital, Charité - Universitätsmedizin Berlin, General Electric Healthcare, F. Hoffmann-La Roche AG, Pfizer Inc., Bayer AG, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Takeda Pharmaceuticals USA Inc., Becton Dickinson and Company, Cook Medical LLC, Terumo Corporation, AngioDynamics Inc., Thermo Fisher Scientific Inc., Illumina Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Incyte Corporation, Seattle Genetics Inc.
North America was the largest region in the oncologists market in 2025. The regions covered in the oncologists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncologists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the oncologists market by increasing the cost of importing diagnostic equipment, imaging systems, and specialized cancer therapeutics, affecting hospitals, diagnostic laboratories, and specialty clinics primarily in north america, europe, and asia-pacific. While tariffs may raise operational expenses, they also incentivize local production, investment in domestic manufacturing of medical devices and therapies, and diversification of supply chains, which can enhance accessibility and reduce reliance on imports.
The oncologists market research report is one of a series of new reports that provides oncologists market statistics, including oncologists industry global market size, regional shares, competitors with a oncologists market share, detailed oncologists market segments, market trends and opportunities, and any further data you may need to thrive in the oncologists industry. This oncologists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncologists are healthcare professionals who specialize in the diagnosis and treatment of cancer. They assess patients, identify the presence and type of cancer, and recommend appropriate treatment options. Oncologists are involved in the overall treatment and care of individuals with cancer.
The primary areas of cancer diagnostics and treatment handled by oncologists include cancer diagnostics and cancer treatment. Cancer diagnostics involves testing procedures used to confirm the presence of cancer and determine the tumor type. These services address indications such as lung cancer, colorectal cancer, breast cancer, liver cancer, bladder cancer, head and neck cancer, and prostate cancer, with end users including hospitals, diagnostic laboratories, diagnostic imaging centers, specialty clinics, academic institutions, and others.
The oncologists market includes revenues earned by entities by providing diagnoses and treats cancer, radiation oncologists and surgical oncologists. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Oncologists Market Characteristics
3. Oncologists Market Supply Chain Analysis
4. Global Oncologists Market Trends and Strategies
5. Oncologists Market Analysis of End Use Industries
7. Global Oncologists Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Oncologists Total Addressable Market (TAM) Analysis for the Market
9. Oncologists Market Segmentation
10. Oncologists Market Regional and Country Analysis
11. Asia-Pacific Oncologists Market
12. China Oncologists Market
13. India Oncologists Market
14. Japan Oncologists Market
15. Australia Oncologists Market
16. Indonesia Oncologists Market
17. South Korea Oncologists Market
18. Taiwan Oncologists Market
19. South East Asia Oncologists Market
20. Western Europe Oncologists Market
21. UK Oncologists Market
22. Germany Oncologists Market
23. France Oncologists Market
24. Italy Oncologists Market
25. Spain Oncologists Market
26. Eastern Europe Oncologists Market
27. Russia Oncologists Market
28. North America Oncologists Market
29. USA Oncologists Market
30. Canada Oncologists Market
31. South America Oncologists Market
32. Brazil Oncologists Market
33. Middle East Oncologists Market
34. Africa Oncologists Market
36. Oncologists Market Competitive Landscape and Company Profiles
37. Oncologists Market Other Major and Innovative Companies
40. Oncologists Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Oncologists Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses oncologists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oncologists? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncologists market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Cancer Diagnostics And Treatment: Cancer Diagnostics; Cancer Treatment2) By Indication: Lungs Cancer; Colorectal Cancer; Breast Cancer; Liver Cancer; Bladder Cancer; Head And Neck Cancer; Prostate Cancer; Other Indications
3) By End Use: Hospitals; Diagnostic Laboratories; Diagnostic Imaging Centers; Specialty Clinics; Academia; Other End Uses
Subsegments:
1) By Cancer Diagnostics: Imaging Tests; Biopsy; Blood Tests; Molecular Diagnostics; Genetic Testing2) By Cancer Treatment: Chemotherapy; Radiation Therapy; Immunotherapy; Targeted Therapy; Hormone Therapy; Stem Cell Transplant
Companies Mentioned: Abramson Cancer Center; MD Anderson Cancer Center of the University of Texas; Lilavati Hospital & Research Centre; Mount Elizabeth Hospital; Mount Miriam Cancer Hospital; Charité - Universitätsmedizin Berlin; General Electric Healthcare; F. Hoffmann-La Roche AG; Pfizer Inc.; Bayer AG; Merck & Co. Inc.; AbbVie Inc.; Amgen Inc.; Takeda Pharmaceuticals USA Inc.; Becton Dickinson and Company; Cook Medical LLC; Terumo Corporation; AngioDynamics Inc.; Thermo Fisher Scientific Inc.; Illumina Inc.; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Eli Lilly and Company; Gilead Sciences Inc.; Regeneron Pharmaceuticals Inc.; Incyte Corporation; Seattle Genetics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Oncologists market report include:- Abramson Cancer Center
- MD Anderson Cancer Center of the University of Texas
- Lilavati Hospital & Research Centre
- Mount Elizabeth Hospital
- Mount Miriam Cancer Hospital
- Charité - Universitätsmedizin Berlin
- General Electric Healthcare
- F. Hoffmann-La Roche AG
- Pfizer Inc.
- Bayer AG
- Merck & Co. Inc.
- AbbVie Inc.
- Amgen Inc.
- Takeda Pharmaceuticals USA Inc.
- Becton Dickinson and Company
- Cook Medical LLC
- Terumo Corporation
- AngioDynamics Inc.
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Novartis AG
- Eli Lilly and Company
- Gilead Sciences Inc.
- Regeneron Pharmaceuticals Inc.
- Incyte Corporation
- Seattle Genetics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 21.09 Billion |
| Forecasted Market Value ( USD | $ 25.07 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
